{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:19:34Z","timestamp":1774984774963,"version":"3.50.1"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NOVARTIS Pharma France"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To estimate the frequency of reporting composite indices evaluating axial spondyloarthritis (axSpA) disease activity in daily practice and to assess its impact on the secukinumab (SEC) retention rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Study design: Retrospective, multicentre. Data collected: (1) <jats:underline>Recommended composite indices<\/jats:underline>: Bath Ankylosing Spondyltitis Disease Activity Index (BASDAI) +C reactive protein\u2009or Ankylosing Spondylitis Disease Activity Score (ASDAS) at the time of initiation of SEC and at least once during the first year of follow-up; (2) <jats:underline>Drug retention rate<\/jats:underline>: percentage of patients still on SEC over time according to whether at least one recommended composite index had been optimally reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A recommended composite index has been collected in 22% of the 906 enrolled axSpA patients. The percentage of patients still on treatment after 1, 2 and 3 years of follow-up was greater in those for whom at least one composite index had been optimally reported (respectively, 64% (57\u201371) vs 57% (54\u201361), 55% (48\u201362) vs 41% (38\u201345) and 52% (44\u201359) vs 38% (34\u201342), log rank test, p=0.016) with a lower risk of SEC discontinuation for these patients (HR: 0.70 (95% CI 0.5 to 0.88), Cox model, p=0.003).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study suggests that reporting of recommended composites indices for monitoring axSpA might be associated with higher retention rates of biological therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002106","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T13:13:53Z","timestamp":1647522833000},"page":"e002106","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"first","affiliation":[{"name":"Hopital Cochin, Rheumatology, University of Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Lucas","sequence":"additional","affiliation":[{"name":"Biostatistics, RCTs, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Desfleurs","sequence":"additional","affiliation":[{"name":"Medical affairs, Novartis Pharma SAS, Rueil-Malmaison, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Lukas","sequence":"additional","affiliation":[{"name":"Rhumatologie, University of Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Saraux","sequence":"additional","affiliation":[{"name":"Rheumatologt, Universit\u00e9 de Bretagne Occidentale, Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tournadre","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Ruyssen-Witrand","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-5780","authenticated-orcid":false,"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 de Franche-Comt\u00e9, Besancon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 de Tours, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-0544","authenticated-orcid":false,"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[{"name":"Rheumatology, Hopital Albert Chenevier, Creteil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"2025090313445888000_8.1.e002106.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090313445888000_8.1.e002106.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090313445888000_8.1.e002106.3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jbspin.2018.01.006","article-title":"2018 update of French Society for rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2025090313445888000_8.1.e002106.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2025090313445888000_8.1.e002106.5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrrheum.2013.93","article-title":"Spondyloarthritis: is it time to replace BASDAI with ASDAS?","volume":"9","author":"Machado","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313445888000_8.1.e002106.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025090313445888000_8.1.e002106.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204055"},{"key":"2025090313445888000_8.1.e002106.8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001008"},{"key":"2025090313445888000_8.1.e002106.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091793"},{"key":"2025090313445888000_8.1.e002106.10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbspin.2006.05.015","article-title":"Practice patterns in outpatient rheumatology: a pilot evaluation of medical file content. RHEVER network (r\u00e9seau h\u00f4pital et ville en rhumatologie)","volume":"74","author":"Fechtenbaum","year":"2007","journal-title":"Joint Bone Spine"},{"key":"2025090313445888000_8.1.e002106.11","doi-asserted-by":"crossref","unstructured":"Portier E , Dougados M , Roux C . Disease activity outcome measures are only available in half of the electronic medical files of patients with axial spondyloarthritis followed in an outpatient clinic : the results of an audit of a tertiary-care rheumatology department. Ann Rheum Dis;80.","DOI":"10.1136\/annrheumdis-2021-eular.2120"},{"key":"2025090313445888000_8.1.e002106.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219585"},{"key":"2025090313445888000_8.1.e002106.13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13075-015-0897-6","article-title":"Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice","volume":"17","author":"Wallman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090313445888000_8.1.e002106.14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001280"},{"key":"2025090313445888000_8.1.e002106.15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001079"},{"key":"2025090313445888000_8.1.e002106.16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000762","article-title":"Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study","volume":"4","author":"Lindstr\u00f6m","year":"2018","journal-title":"RMD Open"},{"key":"2025090313445888000_8.1.e002106.17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000762"},{"key":"2025090313445888000_8.1.e002106.18","unstructured":"Etude fran\u00e7aise observationnelle r\u00e9trospective \u00e9valuant si les signes objectifs d\u2019inflammation sont associ\u00e9s la r\u00e9tention sous traitement par secukinumab 1 an chez des patients trait\u00e9s pour une spondyloarthrite. Available: https:\/\/www.health-data-hub.fr\/projets\/etude-francaise-observationnelle-retrospective-evaluant-si-les-signes-objectifs"},{"key":"2025090313445888000_8.1.e002106.19","doi-asserted-by":"crossref","unstructured":"Rubin DB , ed. Multiple Imputation for Nonresponse in Surveys. Wiley Classics Library Series, 1987.","DOI":"10.1002\/9780470316696"},{"key":"2025090313445888000_8.1.e002106.20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13012-019-0922-2","article-title":"Implementation Science and Implementation Science Communications: our aims, scope, and reporting expectations","volume":"14","author":"Sales","year":"2019","journal-title":"Implement Sci"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:45:06Z","timestamp":1756932306000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,17]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/rmdopen-2021-002106"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002106","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}